EE9900050A - Rho kinaasi inhibiitorit sisaldav farmatseutiline aine - Google Patents

Rho kinaasi inhibiitorit sisaldav farmatseutiline aine

Info

Publication number
EE9900050A
EE9900050A EEP199900050A EE9900050A EE9900050A EE 9900050 A EE9900050 A EE 9900050A EE P199900050 A EEP199900050 A EE P199900050A EE 9900050 A EE9900050 A EE 9900050A EE 9900050 A EE9900050 A EE 9900050A
Authority
EE
Estonia
Prior art keywords
therapeutic agent
agent
kinase inhibitor
rho kinase
pharmaceutical agent
Prior art date
Application number
EEP199900050A
Other languages
English (en)
Estonian (et)
Inventor
Uehata Masayoshi
Ono Takashi
Yamagami Keiji
Satoh Hiroyuki
Kawahara Toshio
Original Assignee
Yoshitomi Pharmaceutical Industries, Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=16622116&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EE9900050(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Yoshitomi Pharmaceutical Industries, Ltd. filed Critical Yoshitomi Pharmaceutical Industries, Ltd.
Publication of EE9900050A publication Critical patent/EE9900050A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4409—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 4, e.g. isoniazid, iproniazid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Virology (AREA)
  • AIDS & HIV (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Materials Applied To Surfaces To Minimize Adherence Of Mist Or Water (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Pyridine Compounds (AREA)
EEP199900050A 1996-08-12 1997-08-08 Rho kinaasi inhibiitorit sisaldav farmatseutiline aine EE9900050A (et)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP21240996 1996-08-12
PCT/JP1997/002793 WO1998006433A1 (fr) 1996-08-12 1997-08-08 MEDICAMENTS COMPRENANT UN INHIBITEUR DE LA Rho KINASE

Publications (1)

Publication Number Publication Date
EE9900050A true EE9900050A (et) 1999-08-16

Family

ID=16622116

Family Applications (1)

Application Number Title Priority Date Filing Date
EEP199900050A EE9900050A (et) 1996-08-12 1997-08-08 Rho kinaasi inhibiitorit sisaldav farmatseutiline aine

Country Status (26)

Country Link
US (3) US6218410B1 (xx)
EP (1) EP0956865B2 (xx)
JP (1) JP3669711B2 (xx)
KR (2) KR100595740B1 (xx)
CN (1) CN100389828C (xx)
AT (1) ATE359822T1 (xx)
AU (1) AU738620B2 (xx)
BG (4) BG63991B1 (xx)
BR (1) BR9711154A (xx)
CA (1) CA2263425C (xx)
CZ (1) CZ301044B6 (xx)
DE (1) DE69737631T3 (xx)
DK (1) DK0956865T4 (xx)
EE (1) EE9900050A (xx)
ES (1) ES2286834T5 (xx)
HK (1) HK1022436A1 (xx)
HU (1) HU229864B1 (xx)
IL (1) IL128456A0 (xx)
IS (1) IS4973A (xx)
NO (1) NO990622L (xx)
NZ (2) NZ334613A (xx)
PL (1) PL331561A1 (xx)
PT (1) PT956865E (xx)
RU (3) RU2206321C2 (xx)
SI (1) SI0956865T2 (xx)
WO (1) WO1998006433A1 (xx)

Families Citing this family (201)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN100389828C (zh) * 1996-08-12 2008-05-28 三菱制药株式会社 含Rho激酶抑制剂的药物制剂
WO1999054306A1 (fr) * 1997-03-10 1999-10-28 Hiroyoshi Hidaka Derives isoquinolinesulfonamide et medicaments integrant ces derives comme principe actif
US20080233098A1 (en) * 1997-10-31 2008-09-25 Mckerracher Lisa RHO Family Antagonists and Their Use to Block Inhibition of Neurite Outgrowth
DE69927936T2 (de) * 1998-08-17 2006-06-29 Mitsubishi Pharma Corp. Präventiva/mittel zur glaukombehandlung
US7169783B2 (en) * 1998-11-02 2007-01-30 Universite De Montreal (+)-Trans-4-(1-aminoethyl)-1-(4-pyridycarbamoyl)-cyclohexane and method for promoting neural growth in the central nervous system and in a patient at a site of neuronal lesion
EP1163910B1 (en) 1999-03-25 2007-09-26 Mitsubishi Pharma Corporation Rho kinase inhibitors for the prevention or treatment of interstitial pneumonia and pulmonary fibrosis
AU3328600A (en) * 1999-03-25 2000-10-16 Santen Pharmaceutical Co. Ltd. Ocular tension-lowering agents
CN1358102A (zh) * 1999-04-22 2002-07-10 三菱制药株式会社 血管狭窄预防治疗药
JP4509395B2 (ja) * 1999-04-27 2010-07-21 田辺三菱製薬株式会社 肝臓疾患の予防治療薬
AU5250400A (en) * 1999-06-18 2001-01-09 Mitsubishi Pharma Corporation Osteogenesis promoters
JP2001081031A (ja) * 1999-08-30 2001-03-27 Schering Ag 溶解性および経口吸収性を改善したベンズアミド誘導体含有製剤
WO2001017562A1 (en) * 1999-09-02 2001-03-15 Yamanouchi Pharmaceutical Co., Ltd. Osteogenesis promoting agents
AU7451200A (en) * 1999-09-29 2001-04-30 Mitsubishi Pharma Corporation Analgesics
US7217722B2 (en) 2000-02-01 2007-05-15 Kirin Beer Kabushiki Kaisha Nitrogen-containing compounds having kinase inhibitory activity and drugs containing the same
EP1270570B1 (en) 2000-03-16 2006-05-31 Mitsubishi Pharma Corporation Amide compounds and use thereof
JP4776138B2 (ja) 2000-03-31 2011-09-21 田辺三菱製薬株式会社 腎臓疾患予防・治療剤
US6930115B2 (en) 2000-06-23 2005-08-16 Mitsubishi Pharma Corporation Antitumor effect potentiators
MXPA03002411A (es) * 2000-09-20 2003-06-19 Merck Patent Gmbh 4-amino-quinazolinas.
AU2001293817A1 (en) * 2000-09-20 2002-04-02 Merck Patent Gmbh 4-amino-quinazolines
JP4582561B2 (ja) * 2000-10-23 2010-11-17 旭化成ファーマ株式会社 移植による血管病変の発生抑制剤
JP2002139493A (ja) * 2000-11-01 2002-05-17 Sumitomo Pharmaceut Co Ltd 新規なハイスループット・スクリーニング方法
CA2325842C (en) 2000-11-02 2007-08-07 Lisa Mckerracher Methods for making and delivering rho-antagonist tissue adhesive formulations to the injured mammalian central and peripheral nervous systems and uses thereof
US20020177207A1 (en) * 2001-03-14 2002-11-28 Myriad Genetics, Incorporated Tsg101-interacting proteins and use thereof
AU2002246924A1 (en) * 2001-01-05 2002-07-16 The Medical College Of Georgia Research Institute, Inc. Treatment of erectile dysfunction with rho-kinase inhibitors
JP2002226375A (ja) * 2001-01-31 2002-08-14 Asahi Kasei Corp 線維化予防、治療剤
US20030068320A1 (en) * 2001-03-02 2003-04-10 Christine Dingivan Methods of administering/dosing CD2 antagonists for the prevention and treatment of autoimmune disorders or inflammatory disorders
PE20020958A1 (es) * 2001-03-23 2002-11-14 Bayer Corp Inhibidores de la rho-quinasa
AU2002250394A1 (en) * 2001-03-23 2002-10-08 Bayer Corporation Rho-kinase inhibitors
US7109208B2 (en) * 2001-04-11 2006-09-19 Senju Pharmaceutical Co., Ltd. Visual function disorder improving agents
US7442686B2 (en) 2001-04-12 2008-10-28 Bioaxone Therapeutique Inc. Treatment of macular degeneration with ADP-ribosyl transferase fusion protein therapeutic compositions
EP1403255A4 (en) * 2001-06-12 2005-04-06 Sumitomo Pharma INHIBITORS OF RHO KINASE
JP5042419B2 (ja) * 2001-08-15 2012-10-03 旭化成ファーマ株式会社 骨形成促進剤および骨形成促進組成物
US7829566B2 (en) * 2001-09-17 2010-11-09 Werner Mederski 4-amino-quinazolines
DE10153605A1 (de) * 2001-11-02 2003-05-28 Morphochem Ag Komb Chemie Verwendung von Inhibitoren der Rho-Kinasen zur Stimulation des Nervenwachstums, zur Inhibition der Narbengewebsbildung und/oder Reduktion eines Sekundärschadens
AU2002349411A1 (en) * 2001-11-30 2003-06-17 Asahi Kasei Pharma Corporation Remedies for primary pulmonary hypertension
FR2833840B1 (fr) * 2001-12-21 2010-06-18 Rytek Methodes et compositions pour le traitement de pathologies respiratoires
ES2305435T3 (es) * 2002-01-10 2008-11-01 Bayer Healthcare Ag Inhibidores de la rho-quinasa.
US6943172B2 (en) * 2002-01-23 2005-09-13 Bayer Pharmaceuticals Corporation Rho-kinase inhibitors
CA2473510A1 (en) * 2002-01-23 2003-07-31 Bayer Pharmaceuticals Corporation Pyrimidine derivatives as rho-kinase inhibitors
GB0206860D0 (en) * 2002-03-22 2002-05-01 Glaxo Group Ltd Compounds
US7645878B2 (en) * 2002-03-22 2010-01-12 Bayer Healthcare Llc Process for preparing quinazoline Rho-kinase inhibitors and intermediates thereof
EP1500643A4 (en) * 2002-04-03 2007-03-28 Dainippon Sumitomo Pharma Co BENZAMIDE DERIVATIVES
US7425618B2 (en) 2002-06-14 2008-09-16 Medimmune, Inc. Stabilized anti-respiratory syncytial virus (RSV) antibody formulations
US20040028716A1 (en) * 2002-06-14 2004-02-12 Marks Andrew R. Use of Y-27632 as an agent to prevent restenosis after coronary artery angioplasty/stent implantation
US7132100B2 (en) 2002-06-14 2006-11-07 Medimmune, Inc. Stabilized liquid anti-RSV antibody formulations
AU2003281152A1 (en) * 2002-07-12 2004-02-02 Yihai Cao A method for inhibiting vascular permeability and tissue edema
US7094789B2 (en) 2002-07-22 2006-08-22 Asahi Kasei Pharma Corporation 5-substituted isoquinoline derivatives
CN100354264C (zh) * 2002-07-22 2007-12-12 旭化成制药株式会社 5－取代异喹啉衍生物及含有它们的药物
DE10233737A1 (de) * 2002-07-24 2004-02-05 Morphochem Aktiengesellschaft für kombinatorische Chemie Verwendung von Modulatoren des Signaltransduktionswegs über die Proteinkinase Fyn zur Behandlung von Tumorerkrankungen
WO2004016739A2 (en) * 2002-08-01 2004-02-26 Caritas St. Elizabeth's Medical Center Of Boston, Inc. Cell modulation using a cytoskeletal protein
ATE546143T1 (de) 2002-08-29 2012-03-15 Santen Pharmaceutical Co Ltd Mittel zur behandlung von glaukom mit einem rho- kinase-hemmer und prostaglandinen
CA2400996A1 (en) * 2002-09-03 2004-03-03 Lisa Mckerracher 1,4-substituted cyclohexane derivatives
EP1550660A1 (en) * 2002-09-12 2005-07-06 Kirin Beer Kabushiki Kaisha Isoquinoline derivatives having kinasae inhibitory activity and drugs containing the same
US20050215601A1 (en) * 2002-09-25 2005-09-29 Santen Pharmaceutical Co., Ltd. Therapeutic agent for rheumatic disease comprising benzamide derivative as active ingredient
US8034831B2 (en) * 2002-11-06 2011-10-11 Celgene Corporation Methods for the treatment and management of myeloproliferative diseases using 4-(amino)-2-(2,6-Dioxo(3-piperidyl)-isoindoline-1,3-dione in combination with other therapies
US7563810B2 (en) 2002-11-06 2009-07-21 Celgene Corporation Methods of using 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myeloproliferative diseases
KR101103141B1 (ko) * 2002-11-18 2012-01-04 산텐 세이야꾸 가부시키가이샤 Ｒｈｏ 키나아제 억제제와 β 차단약으로 이루어진 녹내장치료제
AU2003901270A0 (en) * 2003-03-18 2003-04-03 Medvet Science Pty. Ltd. A method of modulating muscle cell functioning
AU2004221792C1 (en) * 2003-03-18 2009-09-24 Medvet Science Pty. Ltd. A method of modulating smooth muscle cell functioning by modulating sphingosine kinase mediated signalling
GB2400316A (en) * 2003-04-10 2004-10-13 Richard Markoll Electromagnetic stimulation in patients with osteoporosis
KR20120035234A (ko) 2003-04-11 2012-04-13 메디뮨 엘엘씨 재조합 ｉｌ?９ 항체 및 그의 용도
JP4566130B2 (ja) 2003-04-18 2010-10-20 千寿製薬株式会社 角膜知覚回復剤
US20040266755A1 (en) * 2003-05-29 2004-12-30 Schering Aktiengesellschaft Prodrugs of 1-(1-hydroxy-5-isoquinolinesulfonyl) homopiperazine
US20110098232A1 (en) * 2003-05-30 2011-04-28 Zeilig Charles E Methods For The Selective Treatment Of Tumors By Calcium-Mediated Induction Of Apoptosis
WO2004108142A2 (en) * 2003-06-06 2004-12-16 The University Of Manchester Inhibitors of tip-1 for treatment tissue damage
US7160894B2 (en) 2003-06-06 2007-01-09 Asahi Kasei Pharma Corporation Tricyclic compound
WO2005017161A2 (en) * 2003-08-13 2005-02-24 Children's Hospital Medical Center Chimeric peptides for the regulation of gtpases
US7417026B2 (en) * 2003-08-13 2008-08-26 Children's Hospital Medical Center Mobilization of hematopoietic cells
US20060228350A1 (en) * 2003-08-18 2006-10-12 Medimmune, Inc. Framework-shuffling of antibodies
WO2005042743A2 (en) 2003-08-18 2005-05-12 Medimmune, Inc. Humanization of antibodies
US7371850B1 (en) * 2003-08-20 2008-05-13 Myriad Genetics, Inc. Method and composition for reducing expression of ROCK-II
EP1679308B1 (en) 2003-10-15 2013-07-24 Ube Industries, Ltd. Novel indazole derivative
US20050238666A1 (en) * 2003-12-05 2005-10-27 Williams David A Methods of enhancing stem cell engraftment
ES2527118T3 (es) 2003-12-19 2015-01-20 Plexxikon Inc. Compuestos y procedimientos de desarrollo de moduladores de Ret
ATE357932T1 (de) * 2003-12-22 2007-04-15 Alcon Inc Mittel zur behandlung von glaukomatöser retinopathie und optischer neuropathie
CA2548146A1 (en) * 2003-12-22 2005-07-14 Alcon, Inc. Agents for treatment of diabetic retinopathy and drusen formation in macular degeneration
TW200526224A (en) * 2003-12-22 2005-08-16 Alcon Inc Short form c-Maf transcription factor antagonists for treatment of glaucoma
WO2005080394A1 (en) * 2004-02-24 2005-09-01 Bioaxone Therapeutique Inc. 4-substituted piperidine derivatives
WO2005094824A1 (en) * 2004-03-25 2005-10-13 East Carolina University Methods of enhancing cancer therapy by protecting nerve cells
US20080096238A1 (en) * 2004-03-30 2008-04-24 Alcon, Inc. High throughput assay for human rho kinase activity with enhanced signal-to-noise ratio
US20050222127A1 (en) * 2004-03-30 2005-10-06 Alcon, Inc. Use of Rho kinase inhibitors in the treatment of hearing loss, tinnitus and improving body balance
US20060115870A1 (en) * 2004-03-30 2006-06-01 Alcon, Inc. High throughput assay for human Rho kinase activity
ES2671522T3 (es) 2004-04-02 2018-06-06 The Regents Of The University Of California Métodos y composiciones para tratar y prevenir una enfermedad asociada con la integrina alfa V beta 5
ES2553953T3 (es) * 2004-06-03 2015-12-15 Senju Pharmaceutical Co., Ltd. Fármaco para la recuperación de la percepción corneal que contiene un compuesto amida
WO2006047639A2 (en) 2004-10-27 2006-05-04 Medimmune, Inc. Modulation of antibody specificity by tailoring the affinity to cognate antigens
FR2879100B1 (fr) 2004-12-09 2007-07-06 Lionel Bueno Compositions pour le traitement des pathologies oculaires de surface et de la retine
AR054416A1 (es) 2004-12-22 2007-06-27 Incyte Corp Pirrolo [2,3-b]piridin-4-il-aminas y pirrolo [2,3-b]pirimidin-4-il-aminas como inhibidores de las quinasas janus. composiciones farmaceuticas.
EP1830853B1 (en) * 2004-12-27 2011-08-10 Novartis AG Aminopyrazine analogs for treating glaucoma and other rho kinase-mediated diseases
JP4895219B2 (ja) * 2005-02-16 2012-03-14 アステラス製薬株式会社 Ｒｏｃｋ阻害剤を含有する疼痛治療剤
AU2006227377B2 (en) 2005-03-18 2013-01-31 Medimmune, Llc Framework-shuffling of antibodies
CR9465A (es) 2005-03-25 2008-06-19 Surface Logix Inc Compuestos mejorados farmacocineticamente
CA2613512A1 (en) 2005-06-23 2007-01-04 Medimmune, Inc. Antibody formulations having optimized aggregation and fragmentation profiles
BRPI0613597A2 (pt) 2005-06-28 2011-01-18 Sanofi Aventis derivado de isoquinolina como inibidores de rho-quinase
PT1910333E (pt) 2005-07-26 2013-08-01 Sanofi Sa Derivados de isoquinolona substituída com piperidinilo como inibidores da rho-cinase
BRPI0614063A2 (pt) 2005-07-26 2011-03-09 Sanofi Aventis derivados de cicloexilamina isoquinolona
EP2275095A3 (en) 2005-08-26 2011-08-17 Braincells, Inc. Neurogenesis by muscarinic receptor modulation
EP2258357A3 (en) 2005-08-26 2011-04-06 Braincells, Inc. Neurogenesis with acetylcholinesterase inhibitor
BRPI0614974A2 (pt) 2005-08-30 2010-12-14 Asahi Kasei Pharma Corp composto, medicamento, inibidor da fosforilaÇço da cadeia leve regulatària da miosina, inibidor da via rho/rho quinase, e, mÉtodo para tratamento terapÊutico e/ou profilÁtico de glaucoma
WO2007026920A2 (en) 2005-09-02 2007-03-08 Astellas Pharma Inc. Amide derivatives as rock inhibitors
JP4832051B2 (ja) * 2005-10-21 2011-12-07 学校法人順天堂 半月体形成性腎病変治療剤
EP2377530A3 (en) 2005-10-21 2012-06-20 Braincells, Inc. Modulation of neurogenesis by PDE inhibition
ATE551059T1 (de) * 2005-10-26 2012-04-15 Asahi Kasei Pharma Corp Fasudil in kombination mit bosentan zur behandlung von pulmonaler arterieller hypertonie
AU2006308889A1 (en) 2005-10-31 2007-05-10 Braincells, Inc. GABA receptor mediated modulation of neurogenesis
MX2008008328A (es) * 2005-12-22 2008-09-15 Alcon Res Ltd (indazol-5-il)-pirazinas y (1,3-dihidro-indol-2-ona)-pirazinas para tratar enfermedades y condiciones mediadas con rho cinasa.
US7867999B1 (en) 2005-12-22 2011-01-11 Alcon Research, Ltd. Hydroxyamino- and amino-substituted pyridine analogs for treating rho kinase-mediated diseases and conditions
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
WO2007134077A2 (en) 2006-05-09 2007-11-22 Braincells, Inc. 5 ht receptor mediated neurogenesis
EP2382975A3 (en) 2006-05-09 2012-02-29 Braincells, Inc. Neurogenesis by modulating angiotensin
US8227480B2 (en) 2006-06-08 2012-07-24 Ube Industries, Ltd. Indazole derivative having spiro ring structure in side chain
WO2008016016A1 (en) 2006-07-31 2008-02-07 Senju Pharmaceutical Co., Ltd. Aqueous liquid preparation containing amide compound
WO2008022182A1 (en) * 2006-08-16 2008-02-21 The Uab Research Foundation Methods for promoting coupling between bone formation and resorption
EP2292663B1 (en) 2006-08-28 2013-10-02 Kyowa Hakko Kirin Co., Ltd. Antagonistic human light-specific human monoclonal antibodies
GB0617222D0 (en) * 2006-08-31 2006-10-11 Vereniging Het Nl Kanker I Antibiotics
BRPI0716604A2 (pt) 2006-09-08 2013-04-09 Braincells Inc combinaÇÕes contendo um derivado de 4-acilaminopiridina
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
US20090036465A1 (en) * 2006-10-18 2009-02-05 United Therapeutics Corporation Combination therapy for pulmonary arterial hypertension
WO2008063888A2 (en) 2006-11-22 2008-05-29 Plexxikon, Inc. Compounds modulating c-fms and/or c-kit activity and uses therefor
WO2008079945A2 (en) * 2006-12-20 2008-07-03 University Of South Florida Rock inhibitors and uses thereof
AR064420A1 (es) * 2006-12-21 2009-04-01 Alcon Mfg Ltd Composiciones farmaceuticas oftalmicas que comprenden una cantidad efectiva de analogos de 6-aminoimidazo[1,2b]piridazinas, utiles para el tratamiento del glaucoma y/o controlar la presion intraocular normal o elevada(iop).
MX2009006517A (es) 2006-12-27 2009-06-26 Sanofi Aventis Nuevos derivados de isoquinolina e isoquinolinona sustituidos.
ATE490243T1 (de) 2006-12-27 2010-12-15 Sanofi Aventis Cycloalkylaminsubstituierte isochinolin- und isochinolinonderivate
KR20090092303A (ko) 2006-12-27 2009-08-31 사노피-아벤티스 사이클로알킬아민 치환된 이소퀴놀린 유도체
JP5313919B2 (ja) 2006-12-27 2013-10-09 サノフイ 新規な置換イソキノリン及びイソキノリノン誘導体
MY150746A (en) 2006-12-27 2014-02-28 Sanofi Aventis Substituted isoquinoline and isoquinolinone derivatives as inhibitors of rho-kinase
CN101595094B (zh) 2006-12-27 2013-02-20 塞诺菲-安万特股份有限公司 环烷基胺取代的异喹诺酮衍生物
JP5419279B2 (ja) * 2007-01-17 2014-02-19 ウィスコンシン アラムニ リサーチ ファンデーション 改良された幹細胞の培養
WO2008105058A1 (ja) 2007-02-27 2008-09-04 Asahi Kasei Pharma Corporation スルホンアミド化合物
US7964613B2 (en) 2007-02-28 2011-06-21 Asahi Kasei Pharma Corporation Sulfonamide compound
KR101566171B1 (ko) 2007-03-09 2015-11-06 삼성전자 주식회사 디지털 저작권 관리 방법 및 장치
KR101540823B1 (ko) 2007-03-30 2015-07-30 메디뮨 엘엘씨 항체 제제
WO2008134828A2 (en) 2007-05-04 2008-11-13 Katholieke Universiteit Leuven Tissue degeneration protection
ES2396795T3 (es) 2007-07-02 2013-02-27 Asahi Kasei Pharma Corporation Compuesto de sulfonamida y cirstal del mismo
BRPI0814423B1 (pt) 2007-07-17 2022-04-19 Plexxikon, Inc Compostos que modulam quinase e composição farmacêutica compreendendo os mesmos
BRPI0816182A2 (pt) 2007-08-29 2015-04-14 Senju Pharma Co Agente para promoção de adesão celular endotelial corneana
KR20110014183A (ko) * 2008-05-12 2011-02-10 엠네스틱스, 인코포레이티드 학습 및 기억을 개선시키기 위한 화합물
SI2303845T1 (sl) 2008-06-24 2013-12-31 Sanofi Bi- in policiklični substituirani izokinolin in izokinolinski derivati kot inhibitorji rho-kinaze
MY157330A (en) 2008-06-24 2016-05-31 Sanofi Aventis Substituted isoquinolinones as rho kinase inhibitors
JP5714485B2 (ja) 2008-06-24 2015-05-07 サノフイ ６−置換イソキノリン類及びイソキノリノン類
EP2319539A4 (en) 2008-07-24 2012-03-28 Univ Osaka PROPHYLACTIC OR THERAPEUTIC AGENT FOR AXIAL MYOPIA
CN102159547A (zh) * 2008-09-18 2011-08-17 安斯泰来制药株式会社 杂环甲酰胺化合物
EP2177218A1 (en) 2008-10-15 2010-04-21 Medizinische Universität Wien Regenerative therapy
EP2177510A1 (en) 2008-10-17 2010-04-21 Universität des Saarlandes Allosteric protein kinase modulators
WO2010099217A1 (en) 2009-02-25 2010-09-02 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
CR20170089A (es) 2009-04-03 2017-07-17 Plexxikon Inc Composiciones del acido propano-1--sulfonico {3-[5-(4-cloro-fenil)-1h-pirrolo [2,3-b] piridina-3-carbonil] -2,4-difluoro-fenil}-amida y el uso de las mismas
US8329724B2 (en) 2009-08-03 2012-12-11 Hoffmann-La Roche Inc. Process for the manufacture of pharmaceutically active compounds
WO2011021221A2 (en) 2009-08-17 2011-02-24 Reliance Life Sciences Pvt. Ltd. Compositions for spinal cord injury
CN113621576A (zh) 2009-10-16 2021-11-09 斯克里普斯研究所 多能细胞的诱导
WO2011057022A1 (en) 2009-11-06 2011-05-12 Plexxikon, Inc. Compounds and methods for kinase modulation, and indications therefor
CN102188697B (zh) * 2010-03-03 2014-11-05 中国医学科学院药物研究所 重组人Rho激酶在制备药物中的应用
US9782454B2 (en) 2010-04-22 2017-10-10 Longevity Biotech, Inc. Highly active polypeptides and methods of making and using the same
KR102160721B1 (ko) 2010-12-22 2020-09-29 페이트 세러퓨틱스, 인코포레이티드 단세포 분류 및 iPSC의 증강된 재프로그래밍을 위한 세포 배양 플랫폼
WO2012103165A2 (en) 2011-01-26 2012-08-02 Kolltan Pharmaceuticals, Inc. Anti-kit antibodies and uses thereof
RS58455B1 (sr) 2011-02-07 2019-04-30 Plexxikon Inc Jedinjenja i postupci za modulaciju kinaze, i indikacije za njih
AR085279A1 (es) 2011-02-21 2013-09-18 Plexxikon Inc Formas solidas de {3-[5-(4-cloro-fenil)-1h-pirrolo[2,3-b]piridina-3-carbonil]-2,4-difluor-fenil}-amida del acido propano-1-sulfonico
EP2628482A1 (en) 2012-02-17 2013-08-21 Academisch Medisch Centrum Rho kinase inhiitors for use in the treatment of neuroblastoma
US9273006B2 (en) * 2012-05-08 2016-03-01 Syddansk Universitet Anabolic compounds for treating and preventing bone loss diseases
US9150570B2 (en) 2012-05-31 2015-10-06 Plexxikon Inc. Synthesis of heterocyclic compounds
EP4063391A1 (en) 2012-07-25 2022-09-28 Celldex Therapeutics, Inc. Anti-kit antibodies and uses thereof
WO2014059028A1 (en) 2012-10-09 2014-04-17 Igenica, Inc. Anti-c16orf54 antibodies and methods of use thereof
EP2968469A4 (en) 2013-03-15 2016-08-31 Longevity Biotech Inc PEPTIDES COMPRISING NON-ENDOGENIC AMINO ACIDS AND METHODS OF MAKING AND USING SAME
KR102177199B1 (ko) 2013-04-24 2020-11-10 고쿠리쓰다이가쿠호진 규슈다이가쿠 안저질환 치료제
WO2014177699A1 (en) * 2013-05-03 2014-11-06 INSERM (Institut National de la Santé et de la Recherche Médicale) Rhoa (rock) inhibitors for the treatment of enflammatory bowel disease
ES2891755T3 (es) 2013-06-06 2022-01-31 Pf Medicament Anticuerpos anti-C10orf54 y utilizaciones de los mismos
EP3041507B1 (en) 2013-08-26 2021-06-30 BioNTech Research and Development, Inc. Nucleic acids encoding human antibodies to sialyl-lewis a
KR102670874B1 (ko) 2014-03-04 2024-05-31 페이트 세러퓨틱스, 인코포레이티드 개선된 재프로그래밍 방법 및 세포 배양 플랫폼
GB201403775D0 (en) 2014-03-04 2014-04-16 Kymab Ltd Antibodies, uses & methods
US9856324B2 (en) 2014-06-04 2018-01-02 MabVax Therapeutics, Inc. Human monoclonal antibodies to ganglioside GD2
MX2017000181A (es) 2014-06-27 2017-05-01 Univ California Celulas madre limbales de mamifero cultivadas, metodos para generarlas y sus usos.
PL3800202T3 (pl) 2014-12-11 2023-06-12 Pierre Fabre Medicament Przeciwciała przeciwko c10orf54 i ich zastosowania
US10857157B2 (en) 2015-01-26 2020-12-08 BioAxone BioSciences, Inc. Treatment of cerebral cavernous malformations and cerebral aneurysms with rho kinase inhibitors
US10106525B2 (en) 2015-01-26 2018-10-23 BioAxone BioSciences, Inc. Rho kinase inhibitor BA-1049 (R) and active metabolites thereof
US10149856B2 (en) 2015-01-26 2018-12-11 BioAxone BioSciences, Inc. Treatment of cerebral cavernous malformations and cerebral aneurysms with rho kinase inhibitors
CN107847584B (zh) 2015-02-09 2022-01-25 纪念斯隆凯特琳癌症中心 具有人a33抗原和dota金属复合物亲和力的多特异性抗体及其用途
EP3265123B1 (en) 2015-03-03 2022-10-26 Kymab Limited Antibodies, uses & methods
EP3313449B1 (en) 2015-06-24 2020-09-23 Nitto Denko Corporation Ionizable compounds and compositions and uses thereof
EP4088719A1 (en) 2015-10-13 2022-11-16 Institut National de la Santé et de la Recherche Médicale (INSERM) Methods and pharmaceutical compositions for the treatment of retinal capillary non-perfusion
US20180296474A1 (en) 2015-10-13 2018-10-18 INSERM (Institut National de la Santé et de la Recherche Médicale Methods and pharmaceutical compositions for the treatment of retinal capillary non-perfusion
CN108291237B (zh) 2015-10-16 2023-11-21 菲特治疗公司 用于诱导和维护基态多能性的平台
US11253590B2 (en) 2015-12-02 2022-02-22 Stsciences, Inc. Antibodies specific to glycosylated BTLA (B- and T- lymphocyte attenuator)
EP3909983A1 (en) 2015-12-02 2021-11-17 STCube & Co. Inc. Antibodies and molecules that immunospecifically bind to btn1a1 and the therapeutic uses thereof
WO2018083248A1 (en) 2016-11-03 2018-05-11 Kymab Limited Antibodies, combinations comprising antibodies, biomarkers, uses & methods
US11198680B2 (en) 2016-12-21 2021-12-14 BioAxone BioSciences, Inc. Rho kinase inhibitor BA-1049 (R) and active metabolites thereof
JP7369038B2 (ja) 2017-05-31 2023-10-25 ストキューブ アンド シーオー．， インコーポレイテッド Ｂｔｎ１ａ１に免疫特異的に結合する抗体及び分子並びにその治療的使用
AU2018277545A1 (en) 2017-05-31 2019-12-19 Stcube & Co., Inc. Methods of treating cancer using antibodies and molecules that immunospecifically bind to BTN1A1
WO2018226671A1 (en) 2017-06-06 2018-12-13 Stcube & Co., Inc. Methods of treating cancer using antibodies and molecules that bind to btn1a1 or btn1a1-ligands
US10537567B2 (en) 2017-07-11 2020-01-21 BioAxone BioSciences, Inc. Kinase inhibitors for treatment of disease
WO2019073069A1 (en) 2017-10-13 2019-04-18 Boehringer Ingelheim International Gmbh HUMAN ANTIBODIES AGAINST THOMSEN-NEW ANTIGEN (TN)
JPWO2019124488A1 (ja) 2017-12-21 2020-12-17 参天製薬株式会社 セペタプロストとＲｈｏキナーゼ阻害剤との組み合わせ医薬
CN112740043A (zh) 2018-07-20 2021-04-30 皮埃尔法布雷医药公司 Vista受体
EP3843845A4 (en) 2018-08-29 2022-05-11 University Of Massachusetts INHIBITION OF PROTEIN KINASE FOR THE TREATMENT OF FRIEDREICH'S ATAXIA
UY38427A (es) 2018-10-26 2020-05-29 Novartis Ag Métodos y composiciones para terapia con células oculares
CN111116555B (zh) * 2018-10-30 2023-06-02 北京盈科瑞创新药物研究有限公司 一种Rho激酶抑制剂及其制备方法和应用
WO2020193802A1 (en) 2019-03-28 2020-10-01 Fundación De La Comunidad Valenciana Centro De Investigación Príncipe Felipe Polymeric conjugates and uses thereof
WO2021220132A1 (en) 2020-04-27 2021-11-04 Novartis Ag Methods and compositions for ocular cell therapy
CN111707831A (zh) * 2020-07-16 2020-09-25 首都医科大学附属北京朝阳医院 Rock激酶活性在辅助诊断sle以及评价sle病情中的应用
EP4274578A1 (en) 2021-01-11 2023-11-15 Incyte Corporation Combination therapy comprising jak pathway inhibitor and rock inhibitor
CN113262226B (zh) * 2021-04-19 2023-05-16 杭州市第一人民医院 利舒地尔在制备细菌感染治疗药物中的应用
CN118159645A (zh) 2021-10-18 2024-06-07 埃维亚生命科学有限公司 组合物及使用其治疗肝纤维化的方法
AU2022369459A1 (en) 2021-10-22 2024-05-30 Evia Life Sciences Inc. Methods for making extracellular vesicles, and compositions and methods of use thereof
WO2023122213A1 (en) 2021-12-22 2023-06-29 Byomass Inc. Targeting gdf15-gfral pathway cross-reference to related applications
WO2023147107A1 (en) 2022-01-31 2023-08-03 Byomass Inc. Myeloproliferative conditions

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS58121278A (ja) 1982-01-12 1983-07-19 Asahi Chem Ind Co Ltd イソキノリンスルホン酸アミド誘導体
US4456757A (en) † 1981-03-20 1984-06-26 Asahi Kasei Kogyo Kabushiki Kaisha Isoquinolinesulfonyl derivatives and process for the preparation thereof
JPH0227992B2 (ja) 1982-01-14 1990-06-20 Asahi Kasei Kogyo Kk Isokinorinsuruhonirukagobutsu
JPS57200366A (en) * 1981-06-01 1982-12-08 Asahi Chem Ind Co Ltd Isoquinoline compound
JPS5993054A (ja) 1982-11-18 1984-05-29 Asahi Chem Ind Co Ltd イソキノリンスルホン酸アミド誘導体
JPS6081168A (ja) 1983-10-13 1985-05-09 Asahi Chem Ind Co Ltd アミジン誘導体
JPS61227581A (ja) * 1985-04-02 1986-10-09 Asahi Chem Ind Co Ltd 血管拡張剤
US4678783B1 (en) 1983-11-04 1995-04-04 Asahi Chemical Ind Substituted isoquinolinesulfonyl compounds
JPS61152658A (ja) 1984-12-27 1986-07-11 Asahi Chem Ind Co Ltd 置換されたイソキノリンスルホンアミド誘導体
EP0187371B1 (en) † 1984-12-27 1991-06-19 Asahi Kasei Kogyo Kabushiki Kaisha Substituted isoquinolinesulfonyl compounds
JPH0680054B2 (ja) 1985-06-19 1994-10-12 吉富製薬株式会社 ピペリジン誘導体
JPH062741B2 (ja) 1985-10-29 1994-01-12 旭化成工業株式会社 ２級のイソキノリンスルホンアミド誘導体
JP2770497B2 (ja) 1988-11-24 1998-07-02 吉富製薬株式会社 トランス―４―アミノ（アルキル）―１―ピリジルカルバモイルシクロヘキサン化合物およびその医薬用途
WO1990005723A1 (en) † 1988-11-24 1990-05-31 Yoshitomi Pharmaceutical Industries, Ltd. Trans-4-amino(alkyl)-1-pyridylcarbamoyl-cyclohexane compounds and their medicinal use
JP2720348B2 (ja) * 1989-03-30 1998-03-04 旭化成工業株式会社 脳細胞機能障害改善剤
JP3408546B2 (ja) * 1991-02-19 2003-05-19 旭化成株式会社 抗喘息剤
JP2864489B2 (ja) * 1991-02-27 1999-03-03 吉富製薬株式会社 喘息治療剤
JP3275389B2 (ja) * 1991-09-06 2002-04-15 三菱ウェルファーマ株式会社 ４−アミノ（アルキル）シクロヘキサン−１−カルボン酸アミド化合物
DK0641781T3 (da) 1991-09-06 2000-09-18 Yoshitomi Pharmaceutical 4-Amino(alkyl)cyclohexan-1-carboxamidforbindelser og anvendelse af disse
JPH05273821A (ja) 1992-03-24 1993-10-22 Nippon Steel Corp 静電画像形成装置
JP3265695B2 (ja) * 1992-05-12 2002-03-11 三菱ウェルファーマ株式会社 ４−置換アミノ（アルキル）シクロヘキサン−１−カルボン酸アミド化合物
JP2893029B2 (ja) * 1992-08-10 1999-05-17 旭化成工業株式会社 心臓保護剤
JPH0680569A (ja) * 1992-09-03 1994-03-22 Asahi Chem Ind Co Ltd 血小板凝集阻害剤
JP3218356B2 (ja) 1993-03-31 2001-10-15 ヤンマー農機株式会社 管理機
JPH06289679A (ja) * 1993-04-01 1994-10-18 Hitachi Metals Ltd 画像形成方法
JP3464012B2 (ja) * 1993-04-05 2003-11-05 旭化成株式会社 精神症候治療剤
DE4323295C1 (de) * 1993-07-12 1995-02-09 Manfred R Dr Hamm Dosiervorrichtung
JPH0741424A (ja) * 1993-07-28 1995-02-10 Asahi Chem Ind Co Ltd 抗炎症剤
JPH07277979A (ja) * 1994-04-12 1995-10-24 Asahi Chem Ind Co Ltd 過粘性症候群治療または予防剤
EP1195372A1 (en) † 1994-04-18 2002-04-10 Mitsubishi Pharma Corporation N-heterocyclic substituted benzamide derivatives with antihypertensive activity
CN100389828C (zh) * 1996-08-12 2008-05-28 三菱制药株式会社 含Rho激酶抑制剂的药物制剂

Also Published As

Publication number Publication date
KR20050055022A (ko) 2005-06-10
SI0956865T2 (sl) 2011-04-29
SI0956865T1 (sl) 2007-10-31
AU3785197A (en) 1998-03-06
CZ301044B6 (cs) 2009-10-21
ATE359822T1 (de) 2007-05-15
NZ334613A (en) 2002-02-01
HUP9903694A3 (en) 2002-10-28
DE69737631T2 (de) 2007-12-27
DE69737631D1 (de) 2007-05-31
RU2003104284A (ru) 2004-08-27
US6218410B1 (en) 2001-04-17
BG63992B1 (bg) 2003-09-30
KR20000029918A (ko) 2000-05-25
HU229864B1 (en) 2014-10-28
US6451825B1 (en) 2002-09-17
RU2003103606A (ru) 2004-08-27
EP0956865B1 (en) 2007-04-18
BG107195A (en) 2003-05-30
AU738620B2 (en) 2001-09-20
US20020032148A1 (en) 2002-03-14
ES2286834T5 (es) 2011-01-31
NO990622D0 (no) 1999-02-10
CA2263425A1 (en) 1998-02-19
BG103246A (en) 2000-05-31
DK0956865T4 (da) 2010-11-22
IL128456A0 (en) 2000-01-31
EP0956865A4 (en) 2001-05-16
NZ513800A (en) 2001-09-28
CN100389828C (zh) 2008-05-28
PL331561A1 (en) 1999-07-19
US20030134775A1 (en) 2003-07-17
EP0956865A1 (en) 1999-11-17
DK0956865T3 (da) 2007-09-03
HUP9903694A2 (hu) 2000-03-28
DE69737631T3 (de) 2011-08-18
KR100595740B1 (ko) 2006-07-03
CZ46099A3 (cs) 1999-07-14
WO1998006433A1 (fr) 1998-02-19
US6906061B2 (en) 2005-06-14
NO990622L (no) 1999-04-12
HK1022436A1 (en) 2000-08-11
KR100576148B1 (ko) 2006-05-03
BG63991B1 (bg) 2003-09-30
EP0956865B2 (en) 2010-08-18
BG107645A (en) 2004-05-31
CN1233188A (zh) 1999-10-27
JP3669711B2 (ja) 2005-07-13
PT956865E (pt) 2007-07-30
IS4973A (is) 1999-02-11
ES2286834T3 (es) 2007-12-01
CA2263425C (en) 2008-09-30
BR9711154A (pt) 1999-08-17
RU2206321C2 (ru) 2003-06-20

Similar Documents

Publication Publication Date Title
EE9900050A (et) Rho kinaasi inhibiitorit sisaldav farmatseutiline aine
BR9710362A (pt) Composto formula-ao farmaceutica utiliza-ao de um composto processos de tratamento de um ser humano ou animal sofrendo de uma mediada por atividade anormal de cinase de proteina tirosina e para a prepara-ao de um composto
DE69630479D1 (de) Arzneimittel zur Behandlung von entzündlichen Herzkrankheiten
DE69728323D1 (de) Variante des humanen C3a Rezeptors; diagnostische und therapeutische Verwendungen
PT84841A (de) Ungesattigte fettsauren enthaltende zubereitungen fuer die synthese von prostaglandinen und hydroxyfettsaueren in biologischen systemen
DE69528624D1 (de) Anti-Fas Antikörper gegen rheumatische Krankheiten
DE69604228D1 (de) Pupillen Messanordnung und Alzheimer Krankheits Diagnosesystem
DE59006868D1 (de) 2-Alkyl-4-arylmethylaminochinoline, ihre Verwendung und daraus hergestellte Arzneimittel.
HUP9901375A2 (hu) Antigénspecifikus immunszupressziós génterápiában alkalmazható új peptidek
HUP0002346A1 (hu) Emlősök elmezavarainak kezelésére szolgáló gyógyszerkészítmény
ATE184005T1 (de) Oxazolidinone derivate, ihre herstellung und ihre therapeutische verwendung
EA199800417A1 (ru) Фармацевтическая композиция для лечения аутоиммунных заболеваний
NO984651L (no) Anvendelse av benzonaftalenderivater for fremstilling av medikamenter for behandling av sykdommer i sentralnervesystemet
CA2188816A1 (en) Composition containing .alpha.-fodrin or .alpha.- fodrin fragment protein
DE69825395D1 (de) Medikament, behandlungsmethode, prophylaktikum und prophylaxe gegen immunologische erkrankungen von hunden und katzen
NO980384L (no) Fremgangsmåte for fremstilling av fastdoseformer av svært lav-dose legemidler
ATE205841T1 (de) Derivate von 5-naphthalin-1-yl-1,3-dioxanen, ihre herstellung und therapeutische anwendung
NO882724L (no) Smertepreparat.
SE9704463D0 (sv) Novel autoantigen
RU2001123675A (ru) Средство бальзам "ГРААЛЬ" для лечения сердечно-сосудистой системы и заболеваний крови человека
RU93011400A (ru) Лекарственное средство для лечения язвенной болезни желудка и двенадцатиперстной кишки "ахигран"
SE9800359D0 (sv) Pharmaceutical preparation and method for treatment, prevention and diagnosis of gastrooesophageal reflux disease
ID18669A (id) Turunan triterpena dan sediaan farmasi untuk pengobatan penyakit-penyakit hati
TH25792A (th) สูตรผสมริโดเจรลขนาดต่ำ
TH18330B (th) อนุพันธ์กรดไขมัน

Legal Events

Date Code Title Description
HC1A Change of owner name